Brokerages Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) PT at $27.14

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have been given a consensus rating of “Moderate Buy” by the ten ratings firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $27.1429.

A number of research analysts have issued reports on the company. Canaccord Genuity Group cut their price objective on Zevra Therapeutics from $29.00 to $20.00 and set a “buy” rating for the company in a report on Monday, July 27th. Maxim Group increased their price objective on Zevra Therapeutics from $25.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. Guggenheim reduced their target price on shares of Zevra Therapeutics from $24.00 to $23.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. Cantor Fitzgerald lifted their price objective on Zevra Therapeutics from $24.00 to $34.00 and gave the stock an “overweight” rating in a research note on Monday, June 8th. Finally, Wall Street Zen upgraded shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, July 12th.

Insider Transactions at Zevra Therapeutics

In related news, Director Corey Watton sold 12,300 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $11.25, for a total transaction of $138,375.00. Following the completion of the sale, the director directly owned 1,800 shares of the company’s stock, valued at approximately $20,250. This represents a 87.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 3.70% of the company’s stock.

Institutional Investors Weigh In On Zevra Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. AIGH Capital Management LLC acquired a new position in shares of Zevra Therapeutics during the 1st quarter worth about $11,184,000. Dimensional Fund Advisors LP increased its stake in shares of Zevra Therapeutics by 259.2% during the first quarter. Dimensional Fund Advisors LP now owns 554,802 shares of the company’s stock worth $5,168,000 after purchasing an additional 400,336 shares during the period. Hennion & Walsh Asset Management Inc. increased its position in Zevra Therapeutics by 116.6% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 383,706 shares of the company’s stock worth $5,502,000 after buying an additional 206,543 shares during the period. Bank of New York Mellon Corp acquired a new stake in Zevra Therapeutics in the 2nd quarter worth about $2,846,000. Finally, Globeflex Capital L P acquired a new stake in shares of Zevra Therapeutics in the second quarter valued at approximately $2,752,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

Zevra Therapeutics Price Performance

ZVRA opened at $11.84 on Friday. The business has a fifty day simple moving average of $11.68 and a 200 day simple moving average of $11.21. The company has a market capitalization of $703.11 million, a PE ratio of 12.87 and a beta of 0.95. Zevra Therapeutics has a 1 year low of $7.35 and a 1 year high of $15.03.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its earnings results on Wednesday, August 5th. The company reported $0.25 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.14. The business had revenue of $39.66 million for the quarter, compared to analysts’ expectations of $33.88 million. Zevra Therapeutics had a net margin of 42.82% and a return on equity of 54.54%. Equities analysts anticipate that Zevra Therapeutics will post 0.72 earnings per share for the current fiscal year.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc is a rare-disease biopharmaceutical company focused on developing and commercializing treatments for conditions with significant unmet medical needs. The company combines data science, patient-focused drug development and traditional pharmaceutical research to advance therapies for rare metabolic and neurological disorders.

Zevra’s lead commercial product is MIPLYFFA (arimoclomol), which the U.S. Food and Drug Administration approved in 2024 for the treatment of Niemann-Pick disease type C in adults and children at least 2 years old, in combination with miglustat.